Atrial fibrillation is common in elderly patients and is responsible for approximately a quarter of ischemic strokes many of which are cardioembolic and originate from the left atrial appendage. Oral anticoagulation most likely reduces thrombus formation in the left atrial appendage and has proven efficacy and safety in preventing ischemic stroke in patients with atrial fibrillation. However, oral anticoagulation is limited by nonadherence to prescribed medications, drug discontinuation, under dosing, and, for patients treated with vitamin K antagonists, poor control of the international normalized ratio. This CME activity will address professional challenges by reviewing the clinical data for left atrial appendage occlusion device therapy; discussing patient selection criteria; discussing the history of device development; and will conclude discussing post implant anticoagulation therapy and current and upcoming clinical trials.
To receive Category 1 credit for viewing this presentation, the viewer must complete a post-test to evaluate knowledge obtained. Click on the Post Test Button to access this test.
Dates and Times
End Date: 7/1/2023
After completing this continuing medical education activity viewers will be able to
1. Identify patient selection criteria;
2. Identify post left atrial appendage occlusion device implant oral anticoagulation treatment and TEE follow up;
3. Discuss current and upcoming clinical trials;
4. Review new device technologies.
The Center for Continuing Medical Education (CCME) at The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians
The Center for Continuing Medical Education (CCME) at The Ohio State University designates this internet enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.